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VancomycinA phase 3, randomized, double-blind trial was conducted in subjects with diabetic foot infections without
osteomyelitis (primary study) or with osteomyelitis (substudy) to determine the efﬁcacy and safety
of parenteral (intravenous [iv]) tigecycline (150 mg once-daily) versus 1 g once-daily iv ertapenem ±
vancomycin. Among 944 subjects in the primary study who received ≥1 dose of study drug, N85% had type 2
diabetes; ~90% had Perfusion, Extent, Depth/tissue loss, Infection, and Sensation infection grade 2 or 3; and
~20% reported prior antibiotic failure. For the clinically evaluable population at test-of-cure, 77.5% of
tigecycline- and 82.5% of ertapenem ± vancomycin–treated subjects were cured. Corresponding rates for the
clinical modiﬁed intent-to-treat population were 71.4% and 77.9%, respectively. Clinical cure rates in the
substudy were low (b36%) for a subset of tigecycline-treated subjects with osteomyelitis. Nausea and
vomiting occurred signiﬁcantly more often after tigecycline treatment (P=0.003 and P b 0.001, respectively),
resulting in signiﬁcantly higher discontinuation rates in the primary study (nausea P = 0.007, vomiting
P b 0.001). In the primary study, tigecycline did not meet criteria for noninferiority compared with
ertapenem ± vancomycin in the treatment of subjects with diabetic foot infections.
© 2014 Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Over 200 million individuals worldwide have diabetes mellitus,
and with a rapidly increasing prevalence; that number is expected to
exceed 300 million in the next 20 years (Andersen and Roukis, 2007;
Boulton et al., 2005; Wieman, 2005). As longevity and body mass
index of populations around the globe continue to increase, the
incidence of complications related to diabetes is also rising (Andersen
and Roukis, 2007). Complications of the lower extremities are the
most common cause of morbidity and mortality in persons with
diabetes, with approximately 20% requiring hospitalization for
infection (Lipsky et al., 2004; Schweitzer and Morrison, 2004;36-14388459.
pen access under CC BY-NC-ND licensTomas et al., 2000). Globally, every 30 seconds, an amputation of a
lower limb occurs as a result of diabetes (Boulton et al., 2005). In the
United States, diabetes is responsible for 50% of all non-traumatic
amputations (Edmonds and Foster, 2004; Levin, 2002). Amputations
occur approximately 40 times more frequently in persons with
diabetes than in those without (Schweitzer and Morrison, 2004).
Globally, foot infections in persons with diabetes contribute to
signiﬁcant economic and social burdens (Rao, 2005).
Thediagnosisof infection isprimarily clinical (Lipskyet al., 2004;Rao,
2005), and at times, detection of diabetic foot infections may be
challenging (Tomaset al., 2000). Anumberof classiﬁcation systemshave
been devised to characterize diabetic foot infections in an effort to aid
diagnosis, but none have been shown to be reliable (Abbas et al., 2008;
Rao, 2005; Schaper, 2004). Ingeneral, diabetic foot infection is diagnosed
when there is presence of purulent secretions or at least 2 signs or
symptomsof inﬂammation such as erythema,warmth, tenderness, pain,
or induration (Cavanagh et al., 2005; Edmonds and Foster, 2004; Lipsky
et al., 2004; Rao, 2005). The majority of foot infections in persons with
diabetes are caused by Gram-positive species, in particular, Staphylo-
coccus aureus and β-hemolytic streptococci (especially group B)
(Cavanagh et al., 2005; Lipsky et al., 2004). Infections may also bee.
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anaerobic organisms (Lipsky et al., 2004; Rao, 2005). Polymicrobial
infection usually occurs in persons with chronic ulcers or a history of
prior antibiotic treatment (Cavanagh et al., 2005; Lipsky et al., 2004;
Lipsky et al., 2005). In addition to infection, all open wounds become
colonized with microorganisms, which may ultimately result in
superinfections with virulent pathogens such as S. aureus (Cavanagh et
al., 2005; Lipsky et al., 2004). Of note, methicillin-resistant S. aureus
(MRSA) has been recognized as a signiﬁcant concern in treating diabetic
foot infections (Andersen and Roukis, 2007; Lipsky et al., 2004;
Rao, 2005).
While most mild diabetic foot infections can be treated with oral
antimicrobial agents targeting a relatively narrow spectrum of
bacteria, many moderate and almost all severe infections require
therapy with intravenous (iv), broad-spectrum antibiotics adminis-
tered either alone or in combination (Lipsky et al., 2004; Lipsky et al.,
2005). The optimal antimicrobial regimen depends on the culture
results and which organisms are believed to be pathogens, colonizers,
or contaminants (Lipsky et al., 2004; Lipsky et al., 2005). The
consequence of inadequately treated diabetic foot infections is
substantial morbidity and, possibly, lower extremity amputations
(Edmonds and Foster, 2004; Levin, 2002).
Tigecycline is a glycylcycline-class antimicrobial agent with broad-
spectrum in vitro activity including Gram-positive, Gram-negative, and
anaerobic organisms. It is currently approved for use for the treatment
of complicated skin and skin structure infections (cSSSI). Another
attribute of tigecycline that made it appropriate to consider as an
option for patients with diabetes is that it does not require dose
adjustment because of renal impairment (Wyeth Pharmaceuticals Inc,
2012). Based on its in vitro activity and its effectiveness in subjectswith
cSSSI, including results of a subpopulation of subjects with diabetes
evaluated in 2 large-scale phase 3 cSSSI trials (Ellis-Grosse et al., 2005),
and demonstrated penetration of tigecycline into bone (Ji et al., 2008),
a dedicated study to evaluate the role of tigecycline for the treatment
of diabetic foot infections was conducted. The present efﬁcacy and
safety study compared the noninferiority of tigecycline 150 mg once
daily to ertapenem 1 g once daily, with or without adjunctive
vancomycin, in persons with diabetic foot infections requiring iv
therapy for infections of PEDIS (Perfusion, Extent, Depth/tissue loss,
Infection, and Sensation diabetic foot ulcer classiﬁcation system from
the International Working Group on the Diabetic Foot measuring
severity) grades 2 through 4 (American Diabetes Association, 2006)
(i.e., moderate to severe severity).
As noted above, tigecycline has been shown to be effective in the
treatment of cSSSI using a dose of 100 mg followed by 50 mg every
12 hours. Diabetic foot infections are slow to resolve, and as prolonged
treatmentmay be required, once-daily dosing regimens are desirable. A
steady-state half-life of 42.4 hours (Wyeth Pharmaceuticals Inc, 2012)
and the observation that the pharmacodynamic parameter most
predictive of clinical outcome was the ratio of area under the
concentration time curve (AUC) to MIC supported the investigation of
once-daily administration of tigecycline. Single-dose andmultiple-dose
administration ranging between 12.5 mg and 300 mg and 25 mg and
100mg every 12 hours, respectively, in healthy volunteers showed that
tigecycline had dose proportional exposure over the range (Muralid-
haran et al., 2005). The predicted AUC0-24 of 7.1 mg·h/L (1.5 times the
observed steady-state AUC of 4.7 mg·h/L) (Wyeth Pharmaceuticals Inc,
2012) for the 150mg every 24-hour dosewould be expected to result in
an AUC0-24/MIC of 7.1 to 28.4, assuming infections by bacteria with
MICs of 0.25–1 μg/mL. These AUC0-24h/MIC ratios werewithin the range
shown to be associated with efﬁcacy in previous clinical studies
(MacGowan, 2008).
Using a tigecycline dose of 150 mg once daily is certain to cause
nausea and vomiting. Previous clinical studies have shown that it
causes nausea and vomiting at rates of 26% and 18%, respectively
(Wyeth Pharmaceuticals Inc, 2012), when administered twice daily. Itwas anticipated that potentially higher rates might be observed with
the increased dose used, but the inﬂuence of once-daily dosing was
unknown. Given the morbidity associated with diabetic foot in-
fections, it was hoped that subjects and clinicians would be motivated
to continue treatment.
2. Materials and methods
2.1. Subjects
A phase 3, randomized, double-blind study was conducted
between November 2006 and March 2009, to assess individuals
with diabetic foot infection without osteomyelitis (primary study)
and with osteomyelitis (substudy). The international protocol
involved 119 investigational sites in 30 countries. Sites were located
in Europe, the United States, Canada, Latin America, Asia, India,
Australia, and South Africa.
The study protocol was reviewed and approved by the institu-
tional review board or ethical review committee of each participating
center before any study-speciﬁc screening procedure, or informed
consent was obtained. This study was conducted in accordance with
the International Conference on Harmonisation Guideline for Good
Clinical Practice and the ethical principles that have their origins in
the Declaration of Helsinki.
Eligible subjects included hospitalized men and women aged
18 years or older with diabetes mellitus (per the American Diabetes
Association criteria) (American Diabetes Association, 2006) who had a
foot infection that did not extend above the knee. Signs and symptoms
of the infection had to show a PEDIS infection grade from 2 to 4 and a
perfusion grade from 1 to 2 (Schaper, 2004). In addition, the infection
had to be of acute onset or a worsening within 14 days prior to the
screeningvisit. Subjectswhohadosteomyelitis diagnosedatbaseline [as
evidencedmagnetic resonance imaging (MRI) or bone biopsy] were not
evaluable for the primary study butwere eligible for enrollment into the
osteomyelitis substudy. Subjects could not have received more than 48
hours of a prior antibiotic treatment unless considered a prior treatment
failure, deﬁnedasworseningorno improvement in the clinical signsand
symptoms of their diabetic foot infection despite exposure to antibiotic
therapy and institution of nonpharmacological standards of care, and
either: 1) a Gram stain from the infection site showingwhite blood cells
and a potential pathogen or 2) culture results showing a pathogen
resistant to prior antibiotics.
Potential study participants were excluded if they had infections that
were categorized as necrotizing fasciitis, crepitant cellulitis, wet
gangrene, gas gangrene, ecthyma gangrenosum, or which involved
implanted prostheticmaterial or devices thatwere not to be removed, or
infection known or suspected to be caused by a pathogen known to be
resistant to either study drug. Once enrolled, subjects whowere found to
have a pathogen thatwas resistant to tigecycline or comparator as part of
a polymicrobial infection could continue to receive the investigational
product if they were responding favorably (based on the investigator’s
medical judgment). Subjects found to have a monomicrobial infection
with a pathogen that was resistant to tigecycline or comparator had the
investigational product discontinued and were withdrawn from the
study. Subjects with severely impaired arterial supply to any portion of
the affected foot or requiring anticipated complete resection or
amputation of the infected anatomical site within 1 month were also
excluded. Participants were also excluded if they were undergoing
hemodialysis, hemoﬁltration, peritoneal dialysis, or plasmapheresis; had
a concomitant condition that would impair the eradication of the
causative bacteria; had a contraindication or hypersensitivity to any of
the study medications or related antibiotics; were neutropenic or were
receiving concomitant immunosuppressive therapy (including the use of
more than40mgof prednisoneor equivalent); had a creatinine clearance
lower than 30 mL/min, any signiﬁcant hepatic disease with aspartate
aminotransferase levels or alanine aminotransferase levels more than 10
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theULN, or thepresence of acutehepatic failure or acute decompensation
of chronic hepatic failure; or had a known or suspected infection (other
than the diabetic foot infection), which would require treatment with a
systemic antibacterial agent. Pregnant or lactating women or fertile
women without contraception were excluded.
Subjects meeting the inclusion and exclusion criteria who were
randomized were included in the intent-to-treat (ITT) population;
participants who received at least 1 dose of study drug were included
in the modiﬁed ITT (mITT) population; and subjects in the mITT
population who had clinical evidence of a diabetic foot infection, with
orwithout osteomyelitis, bymeeting theminimal disease criteriawere
included in the clinicallymITT (c-mITT) population (Fig. 1). Subjects in
the c-mITT population were considered to be clinically evaluable (CE)
if they remained blinded to study drug treatment throughout the trial,
met minimal treatment duration requirements, had a test-of-cure
(TOC) assessment of cure or failure in the appropriate time frame (12–
92 days after the last dose for the primary study without osteomyelitis
and 25–27weeks for subjects in the substudy armwith osteomyelitis),
and did not develop osteomyelitis within 14 days after the start of the
study medication (subjects who developed osteomyelitis N14 days
after the ﬁrst dose of investigational productwere evaluable). Subjects
included in the microbiologically evaluable (ME) population were CE
subjects for whomone ormore causative isolates were identiﬁed from
the baseline culture to be susceptible to both treatment regimens and
for whom classiﬁcation of the microbiologic response at the TOC visit
could be determined.
2.2. Procedures
The primary objective of the present study was to determine the
safety and efﬁcacy of a once-daily dose of tigecycline compared withRandomized Intent-to-trea
(Tigecycline, 483; Ertape
No study drug received = 11
(Tigecycline, 6; Ertapenem, 5)
Modified ITT (mITT) =
(Tigecycline, 477; Ertapen
Clinical mITT (c-mITT)
(Tigecycline, 476; Ertapen
Did not meet minimal 
disease requirements = 2
(Tigecycline, 1; Ertapenem, 1)
No baseline isolate = 192
(Tigecycline, 98; Ertapenem, 94)
Microbiologic mITT (m-mITT) = 750
(Tigecycline, 378; Ertapenem, 372)
No baseline isolates and suscept
(Tigecycline, 92; Ertapene
Fig. 1. Patient distributioertapenem ± vancomycin for the treatment of moderate to severe
diabetic foot infections without osteomyelitis. The secondary objec-
tives were to evaluate the microbiologic efﬁcacy of tigecycline, to
obtain in vitro susceptibility data on tigecycline for a range of bacterial
pathogens isolated from diabetic foot infections, and to evaluate the
safety and efﬁcacy of a once-daily dose of tigecycline in the treatment
of persons who are identiﬁed as having a diabetic foot infection with
conﬁrmed osteomyelitis.
A computerized randomization/enrollment system for automatic
transtelephonic randomization was used to generate a randomization
schedule for each site. At the time of the randomization, study subjects
were stratiﬁed by the presence or absence of osteomyelitis and by the
infection severity component of the PEDIS classiﬁcation system for
diabetic foot infection (grade 2 or 3 versus grade 4). The subjects who
were randomized(1:1) to thearmwithoutosteomyelitiswere randomly
assigned to receive either iv tigecycline or ertapenem, with or without
adjunctive iv vancomycin placebo (tigecycline arm) or vancomycin
(ertapenemarm) for up to 28days, while the subjects randomized (2:1)
to thearmwith osteomyelitiswere treated for up to42days. For subjects
assigned to the tigecycline group, 150 mg of iv tigecycline was
administered once daily in 100 mL of normal saline and infused over
30minutesevery24hours.Forsubjectsassignedtotheertapenemgroup,
1 g of ertapenem in 100 mL normal saline was administered over
30 minutes every 24 hours. The adjunctive therapy was initiated at the
investigator's discretion for coverage against MRSA, coagulase-negative
staphylococci, or enterococci and was also discontinued at the investi-
gator'sdiscretion.Thestudymedicationswerepreparedbyanunblinded
dispenser, andadjunctive therapydosagewasadjustedby theunblinded
dispenser at the request of the investigator according to the package
insert and investigational site's standard of care. After a minimum of 4
doses (at least72hours), studyparticipants couldbedischarged fromthe
hospital and receive outpatient therapy at the investigator's discretion.t (ITT) = 955
nem, 472)
 944
em, 467)
 = 942
em, 466)
Did not meet evaluability criteria = 129
(Tigecycline, 68; Ertapenem, 61)
Clinically Evaluable (CE) = 813
(Tigecycline, 408; Ertapenem, 405)
ibilities =180
m, 88)
Microbiologically Evaluable (ME) = 633
(Tigecycline, 316; Ertapenem, 317)
n – primary study.
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performed a clinical assessment that included a complete physical
examination, an assessment of clinical signs and symptoms of the
infection, a peripheral perfusion assessment and speciﬁed blood
chemistry, hematology, and urinalysis and also imaging with a plain
radiograph of the infected limb. In situations where osteomyelitis was
suspected, a MRI was performed in order to conﬁrm the presence of
osteomyelitis within 14 days after the randomization; a bone biopsy
was accepted when MRI was contraindicated. All sites were allowed
to enroll subjects in the osteomyelitis arm; however, this was
dependent on regional regulatory requirements. The 10 sites that
enrolled patients included Argentina, Canada, Colombia, India,
Mexico, Panama, Russian Federation, South Africa, Switzerland, and
the United States. TheMRIwas evaluated in a central laboratory, and if
the presence of osteomyelitis could not be conﬁrmed for subjects in
the substudy, the participant was not included in the c-mITT
population. At baseline and during the study, topical antiseptics
were permitted for surgical procedure or debridement, and standard
wound care (e.g., off-loading and wet-to-dry saline dressings) was
allowed. In addition, investigators were encouraged to sharply
debride ulcerated wounds at baseline and as often as clinically
indicated. Wounds could be irrigated with sterile water or sterile
normal saline. Concomitant antibiotics and concomitant topical
antimicrobial agents were prohibited during the study.
2.3. Clinical and microbiologic assessment
A baseline blood culture isolate was collected, and a sample of the
infection site for culture was obtained from curettage of the wound
base, biopsy tissue samples, or aspiration of secretions (a swab was
not permitted). Percutaneous bone biopsy was encouraged for
subjects in the osteomyelitis arm.Randomized Intent-to-trea
(Tigecycline, 77; Ertap
No study drug received = 1
(Tigecycline, 1)
Modified ITT (mITT) = 
(Tigecycline, 76; Ertapene
Clinical mITT (c-mITT)
(Tigecycline, 53; Ertapene
Did not meet minimal 
disease requirements = 31
(Tigecycline, 23; Ertapenem, 8)
No baseline isolate = 22
(Tigecycline, 16; Ertapenem, 6)
Microbiologic mITT (m-mITT) = 64
(Tigecycline, 37; Ertapenem, 27)
No baseline isolates and suscep
(Tigecycline, 10; Ertapen
Fig. 2. Patient distribuThe clinical response within the CE and the c-mITT populations at
the TOC visit was the primary endpoint. An investigator blinded to
treatment assessed the nature of the drainage (purulent versus non-
purulent), erythema, induration, tenderness, pain, local warmth, and
extent of the infection. Based on these assessments, the investigator
evaluated the subject's clinical response to therapy (cure, failure, or
indeterminate). At the TOC assessment, a subject was considered by
the investigator to be clinically cured if there had been resolution of
signs and symptoms of infection such that no further antibiotic
therapy was required. A study subject was considered a clinical
failure in the following situations: if there had been inadequate
response to therapy requiring additional antibacterial therapy; if
initial recovery was followed by deterioration requiring further
antibacterial therapy or surgery; if the subject required extirpative
surgical intervention for management of the target infection or
required non-routine surgical treatment more than 48 hours after the
ﬁrst dose of study medication because of failure to improve; or if
there was a development of a new purulent infection. If no evaluation
was possible for any reason (e.g., lost to follow-up), the response to
therapy was deemed indeterminate.
Microbiologic efﬁcacy was evaluated at both the participant level
(eradication [documented or presumed], persistence [documented or
presumed], superinfection, or indeterminate) and the isolate level
(eradication [documented or presumed], persistence [documented or
presumed], or indeterminate). Skin cultures were the principal source
of the baseline isolate; however, a blood isolate could have been used
if no baseline isolate was identiﬁed from the infection site. All
specimens were sent to local laboratories for initial identiﬁcation of
the isolates and were tested for susceptibility to tigecycline by Kirby-
Bauer disk diffusion tests by procedures published by the Clinical
and Laboratory Standards Institute. Primary identiﬁcation and
susceptibility were performed centrally by Covance Centralt (ITT) = 118
enem, 41)
117
m, 41)
 = 86
m, 33)
Did not meet evaluability criteria = 24
(Tigecycline, 15; Ertapenem, 9)
Clinically Evaluable (CE) = 62
(Tigecycline, 38; Ertapenem, 24) 
tibilities = 16
em, 6)
Microbiologically Evaluable (ME) = 46
(Tigecycline, 28; Ertapenem, 18)
tion – substudy.
Table 1
Demographic and baseline characteristics – primary study and substudy (mITT population).
Characteristic Primary study Substudy
Tigecycline Ertapenem Tigecycline Ertapenem
(n = 477) (n = 467) (n = 76) (n = 41)
Age (mean ± SD) (y) 59.6 ± 11.8 59.2 ± 11.4 57.6 ± 13.2 54.1 ± 12.0
Weight (mean ± SD) (kg) 83.1 ± 20.9 83.3 ± 20.8 76.0 ± 21.5 81.1 ± 25.3
Sex
Men, n (%) 300 (62.9) 315 (67.5) 54 (71.1) 28 (68.3)
Women, n (%) 177 (37.1) 152 (32.6) 22 (28.9) 13 (31.7)
PEDIS infection grade
2, n (%) 244 (51.2) 228 (48.8) 10 (13.2) 7 (17.1)
3, n (%) 187 (39.2) 187 (40.0) 62 (81.6) 30 (73.2)
4, n (%) 46 (9.6) 52 (11.1) 4 (5.3) 4 (9.0)
CrCl (mL/min/1.73 m2) (mean ± SD) 105.2 ± 434.7 98.8 ± 297.9 77.5 ± 27.2 83.0 ± 43.2
Type of diabetes
Type I, n (%) 65 (13.6) 68 (14.6) 10 (13.2) 10 (24.4)
Type II, n (%) 412 (86.4) 399 (85.4) 66 (86.8) 31 (75.6)
CrCl = creatinine clearance.
There were no statistically signiﬁcant differences in any characteristics between the treatment groups.
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were determined using a reference broth microdilution method
with fresh Mueller-Hinton medium. Food and Drug Administration
(FDA) breakpoint criteria were used for susceptibility. All strains of S.
aureus, Streptococcus spp., S. pneumoniae, and vancomycin-susceptible
Enterococcus faecalis with tigecycline MIC values of ≤0.5 μg/mL,
≤0.25 μg/mL, ≤0.06 μg/mL, and ≤0.25 μg/mL, respectively, were
considered susceptible (Wyeth Pharmaceuticals Inc, 2012). Tigecy-
cline MIC breakpoints for Enterobacteriaceae were ≤2 μg/mL for
susceptible, 4 μg/mL for intermediate susceptible, and ≥8 μg/mL for
resistant and for anaerobeswere≤4 μg/mL for susceptible, 8 μg/mL for
intermediate susceptible, and ≥16 μg/mL for resistant (Wyeth
Pharmaceuticals Inc, 2012).2.4. Safety evaluation
The safety (mITT) population comprised all subjects who received
at least 1 dose of study medication. Safety assessments included a
physical examination and a 12-lead electrocardiogram (ECG) at
baseline, day 3, last day of study medication, and at the TOC visit;
all ECG readings were interpreted at a validated central laboratory,
eResearch Technology, Inc., (Philadelphia, PA, USA, and Cambridge,
UK). Vital signs (temperature, heart rate, blood pressure, respiratory
rate) and clinical laboratory parameters (hematology, blood chemis-
try and coagulation parameters, and urinalysis) were assessed at
baseline, day 3, and once a week from day 6 to the last day of study
medication, on the last day of study medication, and at the TOC visit.
Adverse events (AEs) were coded and summarized according toTable 2
Infection characteristics – primary study and substudy.
Characteristics Primary study
mITT population Tigecycline (n = 477) Ertap
Prior antibiotic failure, n (%) 100 (21.0) 93 (1
Etiology
New/acute onset, n (%) 288 (60.4) 305 (
Worsening of prior infection, n (%) 189 (39.6) 162 (
Prior amputation at site of infection
Yes, n (%) 82 (17.2) 80 (1
No, n (%) 395 (82.8) 387 (
ME population Tigecycline (n = 316) Ertap
Bacteremia, n (%) 19 (6.0) 24 (7
There were no statistically signiﬁcant differences in any characteristics between the treatmMedDRA, version 11.1 (IFPMA, Geneva, Switzerland). A treatment-
emergent AE (TEAE) was deﬁned as an event that emerged during the
on-therapy period (or 5 days after administration of the last dose) that
was absent before treatment or worsened during the treatment period
relative to the pretreatment state. All AEs and serious AEs (SAEs) were
followed up until the events subsided, returned to baseline or, in case
of permanent impairment, until the condition stabilized.
2.5. Statistical analysis
The noninferiority of tigecycline to ertapenem ± vancomycin was
evaluated for clinical response by using the lower limit of a 2-sided 95%
conﬁdence interval (CI) for the true difference in efﬁcacy (tigecycline
minus ertapenem ± vancomycin) adjusted for the stratiﬁcation
variable used at the time of the randomization (i.e., infection severity).
Noninferiority was concluded if the lower limit of the 2-sided 95% CI
was not less than−10%. Themethod ofMehrotrawas used to calculate
a CI that adjusts for stratiﬁcation (Mehrotra and Railkar, 2000). The
analysis of the microbiologic response was similar to the primary
analysis. Because of the descriptive nature of the osteomyelitis
substudy arm, no formal statistical analysis was planned.
3. Results
Of the 1073 subjects randomized (955 in the primary study and
118 in the substudy), 1061 received treatment and were thus
included in the mITT (safety) population (Figs. 1 and 2). Importantly,
26 subjects (16 tigecycline, 10 ertapenem ± vancomycin) in theSubstudy
enem (n = 467) Tigecycline (n = 76) Ertapenem (n = 41)
9.9) 34 (44.7) 19 (46.3)
65.3) 33 (43.4) 16 (40.0)
34.7) 43 (56.6) 24 (60.0)
7.1) 17 (22.4) 4 (9.8)
82.9) 59 (77.6) 37 (90.2)
enem (n = 317) Tigecycline (n = 28) Ertapenem (n = 18)
.6) 2 (7.1) 1 (5.6)
ent groups.
Table 3
Clinical response at TOC in the primary study and substudy.
Population category Tigecycline Ertapenem Absolute difference (95% CI) Test for noninferiority, P-value
Primary study
CE population n = 408 n = 405
Cure 316 (77.5) 334 (82.5) −5.5 (−11.0, 0.1)a 0.055a
−5.0 (−10.8, 0.7)b 0.0455b
Failure 92 (22.5) 71 (17.5)
c-mITT population n = 476 n = 466
Cure 340 (71.4) 363 (77.9) −6.7 (−12.3, –1.1)a 0.129a
−6.5 (−12.2, –0.7)b 0.120b
Failure 117 (24.6) 86 (18.5)
Indeterminate 19 (4.0) 17 (3.6)
Substudy
CE population n = 38 n = 24
Cure 12 (31.6) 13 (54.2)
Failure 26 (68.4) 11 (45.8)
c-mITT population n = 53 n = 33
Cure 19 (35.8) 21 (63.6)
Failure 27 (50.9) 12 (36.4)
Indeterminate 7 (13.2) 0 (0.0)
a Adjusted analysis.
b Unadjusted analysis.
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with osteomyelitis, although originally thought to have an uncom-
plicated tissue infection. The co-primary efﬁcacy populations included
1028 subjects (942 in the primary study and 86 in the substudy) in the
c-mITT population and 875 subjects (813 in the primary study and 62
in the substudy) in the CE population.
Differences were not observed between the treatment groups for
demographic or baseline medical characteristics for either the
primary study or the substudy (Table 1). Ninety percent of all subjects
in the primary study had a baseline PEDIS infection grade of 2 or 3. In
general, baseline PEDIS infection grades were similar between the
tigecycline and ertapenem ± vancomycin groups. Twenty percent of
the subjects in the primary study and 45% of the subjects in the
substudy had experienced prior antibiotic failure, despite concomi-
tant nonpharmacological standards of care (e.g., routine debride-
ment) (Table 2). Subjects who failed prior antibiotics prior to study
enrollment were commonly receiving beta-lactam antibiotics (72.5%
primary study, 69.8% substudy), quinolones (28.0% primary study,
37.7% substudy), clindamycin (15.0% primary study, 13.2% substudy),
and metronidazole (13.5% primary study, 13.2% substudy). Seventeen
percent of subjects in the primary study and 18% of subjects in the
substudy had an infection at an amputation site. In the primary study,
bacteremia was detected in 6.0% and 7.6% of the ME subjects in the
tigecycline and ertapenem± vancomycin groups, respectively, on the
last day of therapy. In the ME population of the substudy, 2 of 28
tigecycline subjects and 1 of 18 ertapenem ± vancomycin subjects
had bacteremia on the last day of therapy.Table 4
Clinical cure rates with respect to baseline pathogen (n N 10 isolates/group) – primary stud
Baseline isolate Primary study
Tigecycline, n/N (%) Ertapenem
Acinetobacter baumannii 8/10 (80.0) 15/17 (
E. cloacae 20/23 (87.0) 27/31 (
E. faecalis 56/67 (83.6) 56/67 (
E. coli 21/28 (75.0) 28/38 (
Klebsiella oxytoca 12/15 (80.0) 16/19 (
K. pneumoniae 10/15 (66.7) 17/21 (
P. mirabilis 18/24 (75.0) 25/30 (
Pseudomonas aeruginosa 11/19 (57.9) 12/17 (
MSSA 92/116 (79.3) 123/137 (
MRSA 29/44 (65.9) 17/26 (
S. agalactiae 35/40 (87.5) 40/48 (Importantly, in the primary study, there were no statistically
signiﬁcant differences between treatment groups regarding the
proportions of subjects receiving nonpharmacologic treatments or
procedures for their infection (35% of subjects in the tigecycline group
and 38% of subjects in the ertapenem group had debridement at
baseline or while on therapy). Likewise, in the substudy, debridement
at baseline or while on therapy was similar (53% in the tigecycline
group and 44% in the ertapenem group).
The median duration of treatment in the primary study was 11 days
(range, 1–29 days) for subjects treated with tigecycline and 12 days
(range, 1–30 days) for those treated with ertapenem± vancomycin. In
the substudy, themedian duration of tigecycline treatmentwas 25 days
(range, 2–43 days) and ertapenem ± vancomycin treatment was 39
days (range, 5–45 days). Vancomycin placebo was administered to
17.6% (84/477) of the tigecycline-treated subjects, and adjunctive
vancomycin, to 15.6% (73/467) of ertapenem ± vancomycin subjects
in the primary study (c-mITT population). In the substudy, vanco-
mycin placebo was administered to 17.1% (13/76) of tigecycline-
treated subjects, and vancomycin was administered to 34.1% (14/41)
of ertapenem ± vancomycin–treated subjects. It is noteworthy that,
in both the primary study and substudy, more participants discon-
tinued study medication in the tigecycline group (21.0% and 40.8%,
respectively) than in the ertapenem ± vancomycin group (15.4% and
14.6%, respectively). In the primary study, a signiﬁcantly higher
proportion of the subjects treated with tigecycline had medication
stopped due to an AE (see safety section) and per participant request
than the ertapenem ± vancomycin group (2.9% versus 0.9%, P =y and substudy (ME population).
Substudy
, n/N (%) Tigecycline, n/N (%) Ertapenem, n/N (%)
88.2) 1/2 (50.0) 0/0 (0.0)
87.1) 0/1 (0.0) 0/0 (0.0)
83.6) 3/7 (42.9) 3/5 (60.0)
73.7) 3/6 (50.0) 0/1 (0.0)
84.2) - -
81.0) 1/2 (50.0) 2/2 (100.0)
83.3) - -
70.6) 0/1 (0.0) 1/1 (100.0)
89.8) 4/11 (36.4) 1/5 (20.0)
65.4) 0/3 (0.0) 2/3 (66.7)
83.3) 1/6 (16.7) 3/4 (75.0)
Table 5
Summary of MIC data and response for the most clinically relevant baseline isolates – primary study (ME population).
Baseline isolate N Tigecycline MIC range (μg/mL) Tigecycline, MIC50 Tigecycline, MIC90 Clinical cure at TOC, n/N (%) Eradication at TOC, n/N (%)
A. baumannii 27 0.06–4.00 0.50 2.00 8/10 (80.0) 8/10 (80.0)
E. cloacae 54 0.25–1.00 0.50 0.50 20/23 (87.0) 18/23 (78.3)
E. faecalis 134 0.06–0.25 0.12 0.25 56/67 (83.6) 55/67 (82.1)
E. coli 66 0.06–1.00 0.25 0.50 21/28 (75.0) 22/28 (78.6)
K. oxytoca 34 0.25–1.00 0.25 0.50 12/15 (80.0) 14/15 (93.3)
K. pneumoniae 36 0.25–2.00 0.50 2.00 10/15 (66.7) 12/15 (80.0)
P. mirabilis 54 0.50–8.00 2.00 4.00 18/24 (75.0) 16/24 (66.7)
P. aeruginosa 36 4.00–64.00 8.00 32.00 11/19 (57.9) 12/19 (63.2)
MSSA 253 0.03–0.50 0.12 0.25 92/116 (79.3) 83/116 (71.6)
MRSA 70 0.06–0.50 0.12 0.25 29/44 (65.9) 21/44 (47.7)
S. agalactiae 88 0.03–0.25 0.06 0.06 35/40 (87.5) 34/40 (85.0)
475L. Lauf et al. / Diagnostic Microbiology and Infectious Disease 78 (2014) 469–4800.029). Similar ﬁndings for discontinuation due to an AE were
observed in the substudy.3.1. Efﬁcacy
At the TOC assessment in the primary study, 77.5% of tigecycline-
treated subjects and 82.5% of ertapenem ± vancomycin-treated
subjects in the CE population were considered cured, and 71.4% of
those treated with tigecycline subjects and 77.9% of those who
received ertapenem ± vancomycin in the c-mITT population were
considered cured (Table 3). The tigecycline regimen did not meet the
primary study endpoint of noninferiority to the ertapenem ±
vancomycin regimen for the CE population (true difference in
efﬁcacy of tigecycline minus ertapenem ± vancomycin regimen,
−5.5%; 95% CI,−11.0 to 0.1) or c-mITT population (true difference in
efﬁcacy of tigecycline minus ertapenem ± vancomycin regimen,
−6.7; 95% CI,−12.3 to−1.1), as the lower limit of the 95% CI was less
than−10% in both the adjusted and unadjusted analyses. In addition,
the ertapenem± vancomycin regimen had a signiﬁcantly higher cure
rate comparedwith tigecycline in the c-mITT population, based on the
upper 95% CI interval.
The clinical cure rates by baseline isolates for the ME population in
both the primary study and substudy are shown in Table 4. In the
primary study, the cure rates for most baseline isolates were either
slightly higher or similar for ertapenem ± vancomycin as compared
with tigecycline-treated subjects. However, participants in the
tigecycline regimen with Escherichia coli (21/28; 75.0%), MRSA
(29/44; 65.9%), and S. agalactiae infections (35/40; 87.5%) had higher
cure rates compared to subjects receiving ertapenem ± vancomycin
(28/38, 73.7%; 17/26, 65.4%; and 40/48, 83.3%; respectively). The cure
rates for tigecycline-treated participants with methicillin-susceptible
S. aureus (MSSA) or Klebsiella pneumoniae infections were lower than
expected compared with those treated with ertapenem ± vancomy-
cin. For subjects with baseline bacteremia, excluding contaminants, in
the primary study, the clinical cure rate at the TOC visit was 6/7 (86%)
for tigecycline-treated subjects and 14/14 (100%) for ertapenem-
treated subjects.Table 6
Summary of MIC data and response for the most clinically relevant baseline isolates – subs
Baseline isolate N Tigecycline MIC range (μg/mL) Tigecycline, MIC50
A. baumannii 2 0.12–1.00 NA
E. cloacae 1 0.50–0.50 NA
E. faecalis 12 0.03–0.25 0.12
E. coli 7 0.12–0.50 NA
K. pneumoniae 4 0.25–0.50 NA
P. aeruginosa 2 8.00–16.00 NA
MSSA 16 0.06–0.25 0.12
MRSA 6 0.12–0.25 NA
S. agalactiae 10 0.03–0.06 0.06MIC50 and MIC90 data for the tigecycline-treated subjects in the
primary study and substudy ME populations are shown in Tables 5
and 6, respectively, and were generally low for most isolates. In the
primary study, superinfection occurred more frequently in the
tigecycline group than in the ertapenem group (6.6% [21/316] of
tigecycline versus 3.8% [12/317] of ertapenem ± vancomycin). No
single pathogen accounted for the superinfections that occurred in the
primary study, and the organisms associated with the superinfections
in the tigecycline group were generally susceptible to tigecycline.
Three subjects in the tigecycline group of the primary study and
1 subject in the tigecycline group of the osteomyelitis substudy had
microorganisms with decreased susceptibility to tigecycline during
therapy. Speciﬁcally, S. epidermidis (0.06–1.0 mg/L), Proteus mirabilis
(1.0–4.0 mg/L), and Morganella morganii (1.0–4.0 mg/L) isolates
developed resistance as deﬁned by the MIC crossing the susceptible
breakpoint. One Enterobacter cloacae isolate had a 4-fold increase in
MIC (0.5–2.0 mg/L).
3.2. Safety
There were no signiﬁcant differences in underlying medical
conditions between treatment groups. One or more TEAEs were
reported by 71.1% of the tigecycline-treated subjects and 57.0% of
ertapenem ± vancomycin–treated participants in the primary study
(P b 0.001) and 88.2% of tigecycline-treated subjects and 63.4% of
ertapenem± vancomycin–treated subjects in the substudy (P b 0.01).
Table 7 lists the TEAEs that occurred in the primary study and
substudy in ≥3% of subjects in either treatment group of the primary
study. The most commonly reported TEAEs for tigecycline-treated
subjects in the primary study were nausea (39.8%), vomiting (24.7%),
diarrhea (11.3%), hypertension (7.1%), and hypoglycemia (7.1%). The
most commonly reported TEAEs for tigecycline-treated subjects in the
substudy were nausea (48.7%), vomiting (43.4%), diarrhea (27.6%),
and hypoglycemia (21.1%). In the primary study, nausea and vomiting
(P b 0.001), as well as insomnia (P b 0.05), occurred signiﬁcantly more
often in the tigecycline group. In the substudy, nausea and vomiting
(P b 0.001), as well as hypoglycemia (P b 0.05), occurred signiﬁcantly
more often in the tigecycline group.tudy (ME population).
Tigecycline, MIC90 Clinical cure at TOC, n/N (%) Eradication at TOC, n/N (%)
NA 1/2 (50.0) 1/2 (50.0)
NA 0/1 (0.0) 0/1 (0.0)
0.25 3/7 (42.9) 3/7 (42.9)
NA 3/6 (50.0) 5/6 (83.3)
NA 1/2 (50.0) 1/2 (50.0)
NA 0/1 (0.0) 0/1 (0.0)
0.25 4/11 (36.4) 4/11 (36.4)
NA 0/3 (0.0) 0/3 (0.0)
0.06 1/6 (16.7) 2/6 (33.3)
Table 7
TEAEs that occurred in ≥3% of subjects in either treatment group of the primary study.
AE Primary study Substudy
Tigecycline
N = 477, n (%)
Ertapenem
N = 467, n (%)
Tigecycline
N = 76, n (%)
Ertapenem
N = 41, n (%)
Any AE 339 (71.1)a 266 (57.0) 67 (88.2)b 26 (63.4)
Fever 19 (4.0) 15 (3.2) 8 (10.5) 4 (9.8)
Headache 23 (4.8) 19 (4.1) 3 (3.9) 1 (2.4)
Pain 18 (3.8) 12 (2.6) 7 (9.2) 5 (12.2)
Hypertension 34 (7.1) 35 (7.5) 2 (2.6) 5 (12.2)
Diarrhea 54 (11.3) 46 (9.9) 21 (27.6) 5 (12.2)
Nausea 190 (39.8)a 39 (8.4) 37 (48.7)a 7 (17.1)
Vomiting 118 (24.7)a 22 (4.7) 33 (43.4)a 3 (43.4)
Anemia 10 (2.1) 14 (3.0) 4 (5.3) 4 (9.8)
Hypoglycemia 34 (7.1) 24 (5.1) 16 (21.1)b –
SGOT increased 15 (3.1) 19 (4.1) 5 (6.6) 2 (4.9)
SGPT increased 15 (3.1) 18 (3.9) 4 (5.3) 2 (4.9)
Osteomyelitis 22 (4.6) 11 (2.4) 3 (3.9) 1 (2.4)
Insomnia 15 (3.1)c 4 (0.9) 3 (3.9) 1 (2.4)
SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvic transaminase.
TEAE deﬁnition = events from ﬁrst dose through last day of treatment + 5 days.
a P b 0.001.
b P b 0.01.
c P b 0.05.
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primary study discontinued study drug as a result of an AE (n = 42)
compared with the ertapenem ± vancomycin–treated subjects
(n = 27) (P = 0.081). The AEs leading to tigecycline discontinuation
were primarily nausea (2.7%) and vomiting (2.3%); these occurred
signiﬁcantlymore frequently than in ertapenem±vancomycin–treated
subjects (P b 0.01 and P b 0.001, respectively). Tigecycline-treated
subjects in the primary study also had signiﬁcantly more AEs leading to
study withdrawal (2.1%) than ertapenem ± vancomycin–treated
subjects (0.4%) (P= 0.038); however, the reasons were varied. Overall
reasons for study drug discontinuation and study withdrawal, respec-
tively, in the primary study and substudy are shown in Tables 8 and 9.
A total of 141 (13.3%) of the subjects reported 1 ormore SAEs during
the study: in the primary study, 11.9% in the tigecycline group and 10.7%
in the ertapenem±vancomycin group, and in the substudy, 28.9% in the
tigecycline group and 29.3% in the ertapenem ± vancomycin group.
These differences were not statistically signiﬁcant. The most frequently
reported SAEs for tigecycline-treated subjects in the primary study
(occurring in N1% of subjects) were infection and osteomyelitis.
Signiﬁcantly (P b 0.05) more participants in the primary study in the
tigecycline group (2.5%) had osteomyelitis reported as an SAE compared
to subjects in the ertapenem± vancomycin group (0.6%).
There were a total of 10 deaths in the mITT population (primary
study, 6/477 [1.3%] subjects in the tigecycline group and 2/467 [0.4%]
subjects in the ertapenem± vancomycin group; substudy, 1/76 [1.3%]
subjects in the tigecycline group and 1/41 [2.4%] subjects in theTable 8
Study drug discontinuations – primary study and substudy (mITT population).
Reason, n (%) Primary study
Tigecycline (n = 477) Ertapenem (n = 467
Total 100 (21.0) 72 (15.4)
AE 42 (8.8) 27 (5.8)
Death – –
Investigator request 3 (0.6) 2 (0.4)
Lost to follow-up – –
Otherc 27 (5.7) 20 (4.3)
Protocol violation 1 (0.2) 2 (0.4)
Patient request 14 (2.9) 4 (0.9)
Unsatisfactory response – efﬁcacy 13 (2.7) 17 (3.6)
a Fisher exact test.
b P b 0.05.
c The most common other reason was osteomyelitis status.ertapenem± vancomycin group). Most of the AEs with an outcome of
death were related to a vascular or thrombotic event, and none of the
deaths were considered related to study drug by the investigator.
Five of 7 deaths in the tigecycline group and 2 of 3 deaths in the
ertapenem± vancomycin group occurred more than 1 week after the
end of study treatment. All 7 subjects who died in the tigecycline
group were considered cured at the last day of therapy, although 4
assessments of cure were deemed “indeterminate” at TOC because of
non–infection-related death. Note that 7 deaths were recorded as
study withdrawals because they occurred before the TOC visit.
In the primary study, of the 944 participants in the mITT
population with laboratory data, 394 (82.6%) of tigecycline- and 408
(87.4%) of ertapenem ± vancomycin–treated subjects had an
abnormal laboratory test result during therapy considered of potential
clinical importance based on predeﬁned criteria. For individual
laboratory tests, elevated sodium, potassium, and glucose levels
were observed more frequently in the ertapenem± vancomycin arm,
and low potassium, decreased carbon dioxide, low glucose, and
elevated blood, urea, nitrogen (BUN) values were observed more
frequently in the tigecycline arm. In the primary study, the mean
change from baseline for the ﬁnal on-therapy vital signmeasurements
was similar in both treatment arms.
There were no signiﬁcant differences in change from baseline for
ECG intervals between treatment groups in the primary study. Using
the log-linear correction for QTc interval, the median on-study change
from baseline within 3 hours after dosing in the primary study wasSubstudy
) P-valuea Tigecycline (n = 76) Ertapenem (n = 41) P-valuea
0.029b 31 (40.8) 6 (14.6) 0.004b
0.081 11 (14.5) 1 (2.4) 0.054
– – 1 (2.4) 0.350
1.000 2 (2.6) – 0.541
– 2 (2.6) – 0.541
0.371 4 (5.3) – 0.296
0.621 – – –
0.029b 4 (5.3) – 0.296
0.462 8 (10.5) 4 (9.8) 1.000
Table 9
Study withdrawals – primary study and substudy (mITT population).
Reason, n (%) Primary study Substudy
Tigecycline (n = 477) Ertapenem (n = 467) P-valuea Tigecycline (n = 76) Ertapenem (n = 41) P-valuea
Total 55 (11.5) 38 (8.1) 0.082 25 (32.9) 9 (22.0) 0.286
AE 10 (2.1) 2 (0.4) 0.038b 5 (6.6) 6 (14.6) 0.190
Death 4 (0.8) 1 (0.2) 0.374 1 (1.3) 1 (2.4) 1.000
Investigator request 1 (0.2) 1 (0.2) 1.000 1 (1.3) – 1.000
Lost to follow-up 4 (0.8) 11 (2.4) 0.072 2 (2.6) – 0.541
Otherc 27 (5.7) 14 (3.0) 0.055 5 (6.6) – 0.161
Protocol violation – 1 (0.2) 0.495 1 (1.3) – 1.000
Patient request 5 (1.0) 2 (0.4) 0.452 5 (6.6) – 0.161
Unsatisfactory response – efﬁcacy 4 (0.8) 6 (1.3) 0.543 5 (6.6) 2 (4.9) 1.000
a Fisher exact test.
b P b 0.05.
c The most common other reason was osteomyelitis status.
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upper bounds of the 2-sided 90% CI 7.6 and 3.9 ms, respectively. There
were 2 individuals in both treatment arms of the primary study with
QTc intervals that increased by N60mswithin 3 hours after dosing and
1 individual in the tigecycline arm with a QTc interval that was
N500 ms within 3 hours after dosing, but none of these subjects
developed proarrhythmic AEs.
4. Discussion
The ﬁnding of lack of tigecycline noninferiority was unexpected by
the investigators with higher-than-expected cure rates. When the
study was planned, a cure rate of approximately 70% in the CE
population was expected. In a study comparing ertapenem against
piperacillin/tazobactam, the cure rate was 75% (153/204) for
ertapenem and 70.8% (143/202) for piperacillin/tazobactam (Lipsky
et al., 2005). Although it is difﬁcult to compare results from different
clinical trials, the cure rate observed for tigecycline in the current
study (77.5%) was similar to that reported previously for ertapenem,
while the cure rate for ertapenem ± vancomycin in the current trial
(82.5%) was higher than that reported in the previous trial. Of note,
the Lipsky et al (2005) trial used the University of Texas Diabetic
Wound Classiﬁcation scheme to measure the severity of diabetic foot
infection rather than PEDIS.
The tigecycline dosing regimen performed as predicted.
Tigecycline serum concentrations were collected in 106 patients
receiving tigecycline. After 3 days of treatment, the AUC0-24h was
7.42 ± 3.21 mg·h/L, which was the exposure anticipated for the
dose of 150 mg every 24 hours.
Post hoc analyses were performed to try to understand the study
results. Multiple populations and treatment factors were assessed
individually and in combination, including demographic and baseline
factors, co-morbidities, adjunctive therapy, geographic region, frequen-
cy of baseline pathogens, infection characteristics, and prior antibiotic
failure.Other analyses exploredwhether appropriate therapy (e.g., if the
subject received an antibiotic to which the organism was susceptible)
hadbeenadministered.While theﬁndings of these exploratory analyses
do not change the outcome or explain the differences in cure rates
observed in this study, some possible explanations are suggested.
Compared with ertapenem ± vancomycin, more subjects in the
tigecycline group considered to have been cured on the last day of
therapy were subsequently categorized as failures at the TOC
assessment, and duration of therapy for these subjects was shorter in
the tigecycline group. While duration of therapy overall was similar
between the 2 treatment groups, it may be that subjects who ultimately
failed would have had better outcomes with longer treatment. Also, in
the primary study, more subjects in the tigecycline group (n=16) than
ertapenem ± vancomycin (n = 10) group were diagnosed with
osteomyelitis during the ﬁrst 14 days of therapy. For the primary study,magnetic resonance imaging as radiographic assessment at baseline
was not a requirement. It is reasonable to assume that these subjects
had osteomyelitis at baseline and were considered treatment failures.
Differences in bacteria causing the infection and related suscep-
tibility could also cause a difference between treatment outcomes.
Where microbiologic data were available (approximately 78% of
randomized participants), most of the infections were caused by
pathogens with tigecycline MICs that were low, which theoretically
should have led to clinical cure. Decreasing susceptibility or increasing
MIC values has also been reported in small numbers in prior studies,
and the small numbers of individuals withMIC increases on therapy in
this trial do not appear to have contributed to the overall results.
Despite known lower serum concentrations with tigecycline, baseline
bacteremia did not appear to affect the outcomes of the trial given
similar clinical responses.
There were more discontinuations of study medication overall and
for AEs, particularly nausea and vomiting, in the tigecycline arm. Most
of these subjects received additional antibiotic therapy after disconti-
nuing study treatment and were, therefore, considered failures. This
may have further contributed to the differences in efﬁcacy observed.
Finally, it may be that ertapenem ± vancomycin is more effective in
subjects with diabetic foot infection than once-daily tigecycline.
For the osteomyelitis substudy, the cure rates for tigecycline were
low. The substudy was not powered, and the numbers of participants
in the substudy were small, making it difﬁcult to draw conclusions.
Nevertheless, the median treatment duration of 25 days in the
tigecycline group (versus 39 days in the ertapenem ± vancomycin
group) is considered short for the treatment of osteomyelitis and was
due to the relatively high discontinuation and study withdrawal rate
in the tigecycline arm.
From a safety perspective, the frequencies of nausea and vomiting,
as well as discontinuations for these AEs, were higher than in other
tigecycline studies (Babinchak et al., 2005; Ellis-Grosse et al., 2005;
Tanaseanu et al., 2008). When combined, the rates reported in
previous studies, where tigecycline was administered every 12 hours,
are 26% and 18%, respectively, compared with 13% and 9% for
comparators (Wyeth Pharmaceuticals Inc, 2012). Pharmacodynamic
assessment of nausea and vomiting by Rubino et al (2012) in 289
patients with community-acquired pneumonia or hospital-acquired
pneumoniawhowere treatedwith 100mg then 50mg every 12 hours
using classiﬁcation and regression tree analysis showed a threshold
AUC0-24 of 6.87 mg·h/L to be predictive of the occurrence of nausea
and/or vomiting. Patients with AUC0-24 values above and below the
threshold value had an incidence of nausea and/or vomiting of 40.4%
and 17.2%, respectively (P = 0.00015, Chi-square test). The mean
AUC0-24 of 7.42 mg·h/L observed in the current study and its
incidence of nausea and vomiting of 39.8% and 24.7% are consistent
with Rubino's results, suggesting that once-daily treatment did not
improve tolerability.
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after tigecycline were similar to those reported previously and do not
appear to be indicative of decreased renal function (Babinchak et al.,
2005; Ellis-Grosse et al., 2005; Tanaseanu et al., 2008). Finally, there
was no signal that once-daily tigecycline was associated with QTc
prolongation and no proarrhythmic events were reported, similar to
prior phase 3 tigecycline studies (Babinchak et al., 2005; Ellis-Grosse
et al., 2005; Tanaseanu et al., 2008). The frequency of SAEs was similar
between treatment arms. As expected, the mortality rate in this study
was low, with 6 (1.3%) and 2 (0.4%) deaths for tigecycline- and
ertapenem ± vancomycin–treated subjects, respectively, in the
primary study. Most of the deaths were cardiovascular in nature,
which would not be unexpected for this population. Median time to
death was similar between treatment arms, with most of the deaths
occurring after subjects had stopped study treatment and most of the
subjects had been deemed cured at the last day of therapy. This
numerical imbalance is similar to what has been reported in other
tigecycline studies. For the substudy, 1 subject in each treatment
group died.
There are a number of limitations in the present study. Enrollment
was by central randomization, rather than by region, country, or site.
Although the treatment arms were generally balanced by region,
there could have been some differences between treatment arms in
the types of subjects enrolled or differences with respect to standard
practice. One regional difference is that the European Union did not
participate in the osteomyelitis substudy because they required
additional preclinical data due to the longer duration of tigecycline
therapy thanwhat had been evaluated in prior tigecycline studies. The
substudy was not a powered trial, with only descriptive statistics
planned. Although large for an osteomyelitis study, the numbers were
relatively small, particularly for the evaluable population.
The evaluation of new antimicrobial agents for the treatment of
cSSSIs, such as diabetic foot infections, is complex and can be
confounded by many factors (e.g., clinical manifestations inﬂuenced
by immune status, ambiguity of true etiology, and consensus on
evaluable markers of resolution of infection; need and inﬂuence of
surgical intervention on outcomes) (Stevens, 2009). Furthermore, a
recent review, which sought to deﬁne the magnitude of efﬁcacy of
antimicrobial agents and resulting noninferiority margins for studies
of cSSSIs in the absence of placebo-controlled trials, argues that the
current FDA-mandated noninferiority margins for these infections
require updating (Spellberg et al., 2009). It has been suggested that
reasonable noninferiority margins are needed for each type of cSSSI,
which should be weighted for the proportion of enrolled subjects with
cellulitis/erysipelas, wound, or ulcer infections and major abscesses.
Speciﬁcally, they propose that noninferiority margins of 21% for
wound/ulcer infections would preserve at least 50% of antibiotic
efﬁcacy versus placebo in certain patient subpopulations, such as
those with diabetic foot infections.
In summary, although tigecycline has been shown to be efﬁcacious
in subjects with cSSSI, the 150 mg once-daily regimen of tigecycline
evaluated in this trial did not meet the criteria for noninferiority
compared with ertapenem ± vancomycin in the primary study in
subjects with diabetic foot infections. For the substudy in subjects
with osteomyelitis, the cure rates for tigecycline were low. Higher
rates of nausea and vomiting were observed for tigecycline in this trial
than in other phase 3 studies, with higher discontinuation rates for
these AEs. The safety proﬁle of tigecycline was otherwise generally
similar to what has already been established.
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Within each PEDIS grade, cure rates varied by geographic region. For patients with a PEDIS gr
lower in Western Europe and the USA/Canada compared with other regions, despite the fact
less severe illness. For patients with a PEDIS grade of 3, clinical cure rates were lower for tig
patients in Western Europe and the USA/Canada. For patients with a PEDIS grade of 4, clin
regions with the exception of Eastern Europe and Other/India.
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Ertapenem ± vancomycin
Asia Eastern
Europe
Western
Europe
USA/
Canada
Latin
America
Other/
India
86.4
(19/22)
90.6
(87/96)
75.0
(12/16)
52.4
(11/21)
76.2
(16/21)
87.0
(20/23)
87.1
(27/31)
91.8
(78/85)
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57.1
(4/7)
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(17/19)
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(6/8)
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(5/9)
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(15/19)
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(1/2)
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(1/4)
0.0
(0/2)
87.5
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ade of 2, clinical cure rates after tigecycline and ertapenem± vancomycin therapy were
that a higher proportion of patients in the USA/Canada had a PEDIS grade suggestive of
ecycline-treated patients in Western Europe and for ertapenem ± vancomycin–treated
ical cure rates between treatment groups were highly variable (N15% different) across
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